FDA approvals in 2025 included Anktiva, mitomycin, and gemcitabine intravesical systems for BCG-unresponsive and low-grade intermediate-risk NMIBC. Real-world data supported the efficacy and safety of ...
"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and ...
Experts recommend removing unsupported prostate cancer warnings from TRT labels and aligning indications with professional guidelines. Testosterone's Schedule III classification creates barriers to ...
Gepotidacin is now approved for treating uncomplicated urogenital gonorrhea in patients 12 years and older, expanding its previous approval for urinary tract infections. The EAGLE-1 trial showed ...
The Zenflow Spring Implant offers a reversible, durable BPH treatment, preserving natural anatomy with a spring-like implant. The BREEZE study showed a 60% responder rate and 37% IPSS improvement, ...
Mohit Khera, MD, MBA, MPH, recaps key takeaways from an FDA expert panel discussion on testosterone replacement therapy for men. In a recent interview with Urology Times®, Mohit Khera, MD, MBA, MPH, ...
Arvin K. George, MD, discusses the unique design of the VAPOR 2 trial as well as the key findings from the first 110 patients enrolled in the study. Interim data from the VAPOR 2 trial (NCT05683691) ...
Detalimogene voraplasmid is part of the FDA's CMC Development and Readiness Pilot Program, enhancing manufacturing readiness and clinical development for NMIBC treatment. The phase 2 LEGEND trial ...
"The addition of perioperative durvalumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival without adversely affecting patient-reported outcomes,” said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback